- Home
- NRSN vs VNRX Comparison
NRSN vs VNRX Comparison
Compare NRSN & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRSN | VNRX |
|---|---|---|
| Founded | 2017 | N/A |
| Country | Israel | United States |
| Employees | 15 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.4M | 31.9M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | NRSN | VNRX |
|---|---|---|
| Price | $0.86 | $0.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $8.50 | $2.50 |
| AVG Volume (30 Days) | 125.0K | ★ 1.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,233,511.00 |
| Revenue This Year | N/A | $68.22 |
| Revenue Next Year | N/A | $382.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 59.10 |
| 52 Week Low | $0.68 | $0.17 |
| 52 Week High | $2.60 | $0.94 |
Technical Indicators
Market Signals| Indicator | NRSN | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.25 | 36.92 |
| Support Level | $0.85 | $0.17 |
| Resistance Level | $1.30 | $0.27 |
| Average True Range (ATR) | 0.06 | 0.02 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 42.21 | 17.93 |
Price Performance
Historical ComparisonAbout NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
About VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.